A feasibility study of the intraductal administration of chemotherapy

Cancer Prevention Research

Volumn 6, Issue 1, 2013, Pages 51-58

  Love, Susan M ^a   Zhang, Wei ^c   Gordon, Eva J ^a   Rao, Jianyu ^b   Yang, Hongying ^c   Li, Junyao ^c   Zhang, Bailin ^c   Wang, Xiang ^c   Chen, Guoji ^c   Zhang, Baoning ^c  

^a Dr Susan Love Research Foundation   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOXORUBICIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; BREAST DUCT; CANCER CHEMOTHERAPY; CANCER INVASION; CHINA; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; FEASIBILITY STUDY; FEMALE; HUMAN; INTRADUCTAL ADMINISTRATION; MASTECTOMY; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; CARBOPLATIN; CHINA; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEASIBILITY STUDIES; FEMALE; HUMANS; INFLAMMATION; INTERCALATING AGENTS; MIDDLE AGED; NEOPLASM INVASIVENESS; NIPPLES; TIME FACTORS;

EID: 84872713343     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0228     Document Type: Article

References (38)

1. American Cancer Society. Breast Cancer Facts & Figures 2011-2012. Atlanta, GA: American Cancer Society, Inc.
2. Holland R, Hendriks JH, Vebeek AL, Mravunac M, Schuurmans Stekhoven JH. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet 1990; 335: 519-22. (Pubitemid 20073065)
3. Mai KT, Yazdi HM, Burns BF, Perkins DG. Pattern of distribution of intraductal and infiltrating ductal carcinoma: a three-dimensional study using serial coronal giant sections of the breast. Hum Pathol 2000; 31: 464-74. (Pubitemid 30262869)
4. Tot T. DCIS, cytokeratins, and the theory of the sick lobe. Virchows Archiv 2005; 447: 1-8. (Pubitemid 41126233)
5. Wellings SR. A hypothesis of the origin of human breast cancer from the terminal ductal lobular unit. Pathol Res Pract 1980; 166: 515-35. (Pubitemid 10064978)
6. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006; 7: 223-9. (Pubitemid 43286452)
7. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005; 23: 7491-6. (Pubitemid 46291812)
8. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-88. (Pubitemid 28439961)
9. Tirona MT, Sehgal R, Ballester O. Prevention of breast cancer (part II): risk reduction strategies. Cancer Investigation 2010; 28: 1070-7.
10. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2010; 10: CD002748.
11. Nattinger AB. In the clinic. Breast cancer screening and prevention. Ann Intern Med 2010; 152: ITC41.
12. Tuttle TM, Abbott A, Arrington A, Rueth N. The increasing use of prophylactic mastectomy in the prevention of breast cancer. Current Oncology Reports 2010; 12: 16-21.
13. Cuzick J, De Censi A, Arun B, Brown PH, Castiglione M, Dunn B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 2011; 12: 496-503.
14. Bao T, Prowell T, Stearns V. Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond. Am J Ther 2006; 13: 337-48. (Pubitemid 44492255)
15. Ganz PA. Quality-of-life issues in patients with ductal carcinoma insitu. J Natl Cancer Inst Monogr 2010; 2010: 218-22.
16. Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JLS. Intravesical treatments of bladder cancer: review. Pharmaceutical Res 2008; 25: 1500-10.
17. Echarri Gonzalez MJ, Green R, Muggia FM. Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when? Oncology 2011; 25: 156-65, 70.
18. King BL, Love SM. The intraductal approach to the breast: raison d'être. Breast Cancer Res 2006; 8:206.
19. Love SM, Barsky SH. Anatomy of the nipple and breast ducts revisited. Cancer 2004; 101: 1947-57. (Pubitemid 39425369)
20. Cooper A. The anatomy and diseases of the breast. Philadelphia, PA: Lea and Blanchard; 1845.
21. Going JJ, Moffat DF. Escaping from Flatland: clinical and biological aspects of human mammary duct anatomy in three dimensions. J Pathol 2004; 203: 538-44. (Pubitemid 38529033)
22. Ramsay DT, Kent JC, Hartmann RA, Hartmann PE. Anatomy of the lactating human breast redefined with ultrasound imaging. J Anat 2005; 206: 525-34. (Pubitemid 40873207)
23. Rusby JE, Brachtel EF, Michaelson JS, Koerner FC, Smith BL. Breast duct anatomy in the human nipple: three-dimensional patterns and clinical implications. Breast Cancer Res Treat 2007; 106: 171-9. (Pubitemid 350045011)
24. Taneri F, Kurukahvecioglu O, Akyurek N, Tekin EH, Ilhan MN, Cifter C, et al. Microanatomy of milk ducts in the nipple. Eur Surg Res 2006; 38: 545-9. (Pubitemid 44836994)
25. Ohtake T, Kimijima I, Fukushima T, Yasuda M, Sekikawa K, Take-noshita S, et al. Computer-assisted complete three-dimensional reconstruction of the mammary ductal/lobular systems: implications of ductal anastomoses for breast-conserving surgery. Cancer 2001; 91: 2263-72. (Pubitemid 32552811)
26. Goulet RJ, Badve S, Brannon-Peppas L, Rouch D, Huntley C, Storniolo AM. Pilot trial assessing the feasibility of intra-ductal delivery of epirubicin (epi)-containing nanoparticles (NP) via InDuct@ Breast Microcatheter (IDBM). J Clin Oncol 2004; 22(14S):828.
27. Okugawa H, Yamamoto D, Uemura Y, Sakaida N, Tanano A, Tanaka K, et al. Effect of perductal paclitaxel exposure on the development of MNU-induced mammary carcinoma in female S-D rats. Breast Cancer Res Treat 2005; 91: 29-34. (Pubitemid 40684936)
28. Murata S. Ductal access for prevention and therapy of mammary tumors. Cancer Res 2006; 66: 638-45. (Pubitemid 43165923)
29. Stearns V, Mori T, Jacobs LK, Khouri NF, Gabrielson E, Yoshida T, et al. Preclinical and clinical evaluation of intraductally administered agents in early breast cancer. Sci Transl Med 2011; 3:106ra8.
30. Perez EA, Suman VJ, Fitch TR, Mailliard JA, Ingle JN, Cole JT, et al. A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932. Oncology 2005; 69: 117-21. (Pubitemid 41376909)
31. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24: 2786-92. (Pubitemid 46630577)
32. Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carbo-platin and their combination chemotherapy drugs (review). Oncol Rep 2004; 11: 559-95.
33. Jiang W, Lionberger R, Yu LX. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin. Bioanalysis 2011; 3: 333-44.
34. Duggan ST, Keating GM. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma. Drugs 2011; 71: 2531-58.
35. Kim RJ, Peterson G, Kulp B, Zanotti KM, Markman M. Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers. Gynecol Oncol 2005; 97: 374-8. (Pubitemid 40614877)
36. Lokich J. Doxil extravasation injury: a case report. Ann Oncol 1999; 10: 735-6. (Pubitemid 29342383)
37. Singh Y, Gao D, Gu Z, Li S, Rivera KA, Stein S, et al. Influence of molecular size on the retention of polymeric nanocarrier diagnostic agents in breast ducts. Pharm Res 2012; 29: 2377-88.
38. Tondre J, Nejad M, Casano A, Mills D, Love S. Technical enhancements to breast ductal lavage. Ann Surg Oncol 2008; 15: 2734-8.